25 XP   0   0   10

Cymabay Therapeu
Buy, Hold or Sell?

Let's analyse Cymabay together

PenkeI guess you are interested in Cymabay Therapeu. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cymabay Therapeu. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cymabay Therapeu

I send you an email if I find something interesting about Cymabay Therapeu.

Quick analysis of Cymabay (30 sec.)










What can you expect buying and holding a share of Cymabay? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.55
Expected worth in 1 year
$4.78
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$2.23
Return On Investment
6.9%

For what price can you sell your share?

Current Price per Share
$32.48
Expected price per share
$25.37 - $
How sure are you?
50%

1. Valuation of Cymabay (5 min.)




Live pricePrice per Share (EOD)

$32.48

Intrinsic Value Per Share

$-10.12 - $-7.38

Total Value Per Share

$-7.58 - $-4.83

2. Growth of Cymabay (5 min.)




Is Cymabay growing?

Current yearPrevious yearGrowGrow %
How rich?$292.2m$71.5m$136.2m65.6%

How much money is Cymabay making?

Current yearPrevious yearGrowGrow %
Making money-$27.9m-$31.3m$3.4m12.4%
Net Profit Margin-18,378.7%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Cymabay (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#183 / 1016

Most Revenue
#324 / 1016

Most Profit
#769 / 1016

Most Efficient
#966 / 1016

What can you expect buying and holding a share of Cymabay? (5 min.)

Welcome investor! Cymabay's management wants to use your money to grow the business. In return you get a share of Cymabay.

What can you expect buying and holding a share of Cymabay?

First you should know what it really means to hold a share of Cymabay. And how you can make/lose money.

Speculation

The Price per Share of Cymabay is $32.48. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cymabay.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cymabay, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.55. Based on the TTM, the Book Value Change Per Share is $0.56 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.21 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cymabay.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.37-1.1%-0.23-0.7%-0.23-0.7%-0.20-0.6%-0.14-0.4%
Usd Book Value Change Per Share-0.30-0.9%0.561.7%-0.21-0.6%0.050.2%0.060.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.30-0.9%0.561.7%-0.21-0.6%0.050.2%0.060.2%
Usd Price Per Share23.62-14.55-3.96-6.77-6.48-
Price to Earnings Ratio-16.18--106.60--4.30--26.92--26.48-
Price-to-Total Gains Ratio-79.89-60.15--18.89--7.90--50.68-
Price to Book Ratio9.28-8.93-8.50-5.65-24.31-
Price-to-Total Gains Ratio-79.89-60.15--18.89--7.90--50.68-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share32.48
Number of shares30
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.560.05
Usd Total Gains Per Share0.560.05
Gains per Quarter (30 shares)16.731.59
Gains per Year (30 shares)66.936.37
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10675706-4
201341240132
302011910198
4026825802514
5033532503220
6040239203826
7046945904532
8053552605138
9060259305744
10066966006450

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%1.043.01.02.2%
Book Value Change Per Share3.01.00.075.0%4.08.00.033.3%5.015.00.025.0%11.029.00.027.5%12.031.02.026.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.045.00.0%
Total Gains per Share3.01.00.075.0%4.08.00.033.3%5.015.00.025.0%11.029.00.027.5%12.031.02.026.7%

Fundamentals of Cymabay

About Cymabay Therapeu

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California. As of March 22, 2024, CymaBay Therapeutics, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Fundamental data was last updated by Penke on 2024-04-11 03:39:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cymabay Therapeu.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cymabay earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cymabay to the Biotechnology industry mean.
  • A Net Profit Margin of -73,512.3% means that $-735.12 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cymabay Therapeu:

  • The MRQ is -73,512.3%. The company is making a huge loss. -2
  • The TTM is -18,378.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-73,512.3%TTM-18,378.7%-55,133.6%
TTM-18,378.7%YOY--18,378.7%
TTM-18,378.7%5Y-3,675.7%-14,703.0%
5Y-3,675.7%10Y-1,855.9%-1,819.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-73,512.3%-197.2%-73,315.1%
TTM-18,378.7%-210.4%-18,168.3%
YOY--279.3%+279.3%
5Y-3,675.7%-436.8%-3,238.9%
10Y-1,855.9%-599.3%-1,256.6%
1.1.2. Return on Assets

Shows how efficient Cymabay is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cymabay to the Biotechnology industry mean.
  • -9.6% Return on Assets means that Cymabay generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cymabay Therapeu:

  • The MRQ is -9.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.6%TTM-8.0%-1.7%
TTM-8.0%YOY-18.9%+10.9%
TTM-8.0%5Y-12.3%+4.3%
5Y-12.3%10Y-14.8%+2.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.6%-13.6%+4.0%
TTM-8.0%-12.9%+4.9%
YOY-18.9%-11.9%-7.0%
5Y-12.3%-14.2%+1.9%
10Y-14.8%-16.2%+1.4%
1.1.3. Return on Equity

Shows how efficient Cymabay is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cymabay to the Biotechnology industry mean.
  • -14.3% Return on Equity means Cymabay generated $-0.14 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cymabay Therapeu:

  • The MRQ is -14.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.3%TTM-14.8%+0.4%
TTM-14.8%YOY-53.1%+38.3%
TTM-14.8%5Y-21.6%+6.8%
5Y-21.6%10Y-39.3%+17.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.3%-17.0%+2.7%
TTM-14.8%-16.1%+1.3%
YOY-53.1%-15.4%-37.7%
5Y-21.6%-20.0%-1.6%
10Y-39.3%-21.1%-18.2%

1.2. Operating Efficiency of Cymabay Therapeu.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cymabay is operating .

  • Measures how much profit Cymabay makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cymabay to the Biotechnology industry mean.
  • An Operating Margin of -74,557.9% means the company generated $-745.58  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cymabay Therapeu:

  • The MRQ is -74,557.9%. The company is operating very inefficient. -2
  • The TTM is -18,636.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-74,557.9%TTM-18,636.4%-55,921.5%
TTM-18,636.4%YOY--18,636.4%
TTM-18,636.4%5Y-3,727.3%-14,909.1%
5Y-3,727.3%10Y-1,881.2%-1,846.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-74,557.9%-286.1%-74,271.8%
TTM-18,636.4%-224.4%-18,412.0%
YOY--288.4%+288.4%
5Y-3,727.3%-475.2%-3,252.1%
10Y-1,881.2%-624.7%-1,256.5%
1.2.2. Operating Ratio

Measures how efficient Cymabay is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 746.58 means that the operating costs are $746.58 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cymabay Therapeu:

  • The MRQ is 746.579. The company is inefficient in keeping operating costs low. -1
  • The TTM is 186.897. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ746.579TTM186.897+559.682
TTM186.897YOY-+186.897
TTM186.8975Y37.379+149.518
5Y37.37910Y19.021+18.359
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ746.5792.997+743.582
TTM186.8973.247+183.650
YOY-3.766-3.766
5Y37.3795.675+31.704
10Y19.0217.857+11.164

1.3. Liquidity of Cymabay Therapeu.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cymabay is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 10.96 means the company has $10.96 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cymabay Therapeu:

  • The MRQ is 10.960. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.866. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.960TTM12.866-1.906
TTM12.866YOY12.023+0.844
TTM12.8665Y13.721-0.854
5Y13.72110Y9.723+3.998
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.9603.930+7.030
TTM12.8664.251+8.615
YOY12.0235.436+6.587
5Y13.7216.045+7.676
10Y9.7236.363+3.360
1.3.2. Quick Ratio

Measures if Cymabay is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cymabay to the Biotechnology industry mean.
  • A Quick Ratio of 15.80 means the company can pay off $15.80 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cymabay Therapeu:

  • The MRQ is 15.796. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 19.338. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ15.796TTM19.338-3.542
TTM19.338YOY20.409-1.071
TTM19.3385Y21.815-2.477
5Y21.81510Y15.655+6.159
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.7963.629+12.167
TTM19.3384.065+15.273
YOY20.4095.397+15.012
5Y21.8155.993+15.822
10Y15.6556.277+9.378

1.4. Solvency of Cymabay Therapeu.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cymabay assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cymabay to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.33 means that Cymabay assets are financed with 32.8% credit (debt) and the remaining percentage (100% - 32.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cymabay Therapeu:

  • The MRQ is 0.328. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.425. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.328TTM0.425-0.098
TTM0.425YOY0.592-0.167
TTM0.4255Y0.272+0.153
5Y0.27210Y0.345-0.073
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3280.332-0.004
TTM0.4250.334+0.091
YOY0.5920.268+0.324
5Y0.2720.366-0.094
10Y0.3450.390-0.045
1.4.2. Debt to Equity Ratio

Measures if Cymabay is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cymabay to the Biotechnology industry mean.
  • A Debt to Equity ratio of 48.7% means that company has $0.49 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cymabay Therapeu:

  • The MRQ is 0.487. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.829. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.487TTM0.829-0.342
TTM0.829YOY1.648-0.820
TTM0.8295Y0.582+0.247
5Y0.58210Y0.942-0.360
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4870.381+0.106
TTM0.8290.390+0.439
YOY1.6480.334+1.314
5Y0.5820.434+0.148
10Y0.9420.466+0.476

2. Market Valuation of Cymabay Therapeu

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cymabay generates.

  • Above 15 is considered overpriced but always compare Cymabay to the Biotechnology industry mean.
  • A PE ratio of -16.18 means the investor is paying $-16.18 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cymabay Therapeu:

  • The EOD is -22.244. Based on the earnings, the company is expensive. -2
  • The MRQ is -16.176. Based on the earnings, the company is expensive. -2
  • The TTM is -106.598. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-22.244MRQ-16.176-6.068
MRQ-16.176TTM-106.598+90.422
TTM-106.598YOY-4.298-102.299
TTM-106.5985Y-26.923-79.674
5Y-26.92310Y-26.475-0.448
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-22.244-2.315-19.929
MRQ-16.176-2.560-13.616
TTM-106.598-2.664-103.934
YOY-4.298-4.122-0.176
5Y-26.923-6.258-20.665
10Y-26.475-6.108-20.367
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cymabay Therapeu:

  • The EOD is -33.819. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -24.594. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.288. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-33.819MRQ-24.594-9.225
MRQ-24.594TTM-3.288-21.306
TTM-3.288YOY-5.646+2.359
TTM-3.2885Y-7.528+4.241
5Y-7.52810Y-17.724+10.196
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-33.819-3.067-30.752
MRQ-24.594-3.251-21.343
TTM-3.288-3.545+0.257
YOY-5.646-5.595-0.051
5Y-7.528-8.315+0.787
10Y-17.724-8.708-9.016
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cymabay is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 9.28 means the investor is paying $9.28 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cymabay Therapeu:

  • The EOD is 12.757. Based on the equity, the company is expensive. -2
  • The MRQ is 9.277. Based on the equity, the company is overpriced. -1
  • The TTM is 8.931. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD12.757MRQ9.277+3.480
MRQ9.277TTM8.931+0.346
TTM8.931YOY8.503+0.428
TTM8.9315Y5.645+3.286
5Y5.64510Y24.312-18.667
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD12.7571.905+10.852
MRQ9.2772.111+7.166
TTM8.9312.095+6.836
YOY8.5032.836+5.667
5Y5.6453.443+2.202
10Y24.3123.794+20.518
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cymabay Therapeu.

3.1. Institutions holding Cymabay Therapeu

Institutions are holding 103.125% of the shares of Cymabay Therapeu.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31venBio Select Advisor LLC9.67993.6251111111118111117.8749
2023-12-31BlackRock Inc8.37240.00589610239181824323.3348
2023-12-31RA Capital Management, LLC6.04612.5603694000000
2023-12-31Vanguard Group Inc5.49390.003363061495585629.7182
2023-12-31HHG PLC5.31760.0866103797-699687-10.2842
2023-12-31T. Rowe Price Associates, Inc.3.890.014244651612561460134.5516
2023-12-31Perceptive Advisors LLC3.5062.12184024400-18791-0.4648
2023-12-31Jennison Associates LLC3.47840.0703399271143743712.3039
2023-12-31Franklin Resources Inc2.8470.03613267927-39988-1.2089
2023-09-30Holocene Advisors, LP2.71610.2035311768531176850
2023-09-30Octagon Capital Advisors LP2.67787.04093073750-1497168-32.7542
2023-12-31FMR Inc2.66760.00563061996149304895.1624
2023-12-31State Street Corporation2.43750.0032279791651197222.3965
2023-12-31Adage Capital Partners Gp LLC2.28950.12852628000-1497000-36.2909
2023-09-30Point72 Asset Management, L.P.2.11690.1057242992424299240
2023-12-31Geode Capital Management, LLC2.07350.0059238010530454914.6731
2023-12-31Fred Alger Management, LLC1.71440.25081967858-204451-9.4117
2023-12-31Cormorant Asset Management, LLC1.56812.03051800000-2050000-53.2468
2023-12-31Vestal Point Capital LP1.41574.0661162500016250000
2023-12-31First Turn Management LLC1.30455.0791149733114973310
Total 71.612927.442782201060+11159237+13.6%

3.2. Funds holding Cymabay Therapeu

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv3.06970.00733523557-10517-0.2976
2023-12-31US Small-Cap Growth II Equity Comp1.75560.191720151141292718178.9487
2023-12-31T. Rowe Price New Horizons1.75560.192420151141292718178.9487
2023-12-31Janus Henderson Global Life Sciences1.40560.7781613473-60780-3.6303
2023-12-31Janus Henderson Global Life Sciences D1.40560.77441613473-60780-3.6303
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.38930.05031594737-16956-1.0521
2024-01-31Alger Small Cap Focus Composite1.17171.97671344970-134716-9.1044
2024-01-31Alger Small Cap Focus I1.17171.97671344970-134716-9.1044
2023-12-31Janus Selection Global Life Science AUSD1.06070.77771217523-71349-5.5358
2023-11-30MEDICAL BioHealth EUR Acc1.01873.444116928600
2024-01-31Fidelity Small Cap Index0.99820.10871145790194431.7262
2024-02-29Janus Henderson Glb Life Scn I2 USD0.96880.89971112074-95716-7.9249
2024-02-29Fidelity Canadian Large Cp Mlt Ast Bs O0.87121.3608100000010000000
2023-12-31Janus Henderson Triton D0.84570.3362970743-223215-18.6954
2023-12-31Janus Henderson US SMID Cap Growth0.84570.3377970743-223215-18.6954
2024-01-31Fidelity Small Cap Growth0.66710.314765712-55024-6.7042
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.59780.0529686199159002.3721
2024-02-29Franklin Small Cap Growth Adv0.57730.735666270000
2023-12-31Franklin US Small Cap Growth Equity0.57730.564666270000
2024-02-29Fidelity Extended Market Index0.52910.051607311-2943-0.4823
Total 22.682414.930426036189+2530852+9.7%

3.3. Insider Transactions

Insiders are holding 0.516% of the shares of Cymabay Therapeu.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-12Janet DorlingSELL600031.97
2024-01-19Charles McwherterSELL1840323.67
2024-01-16Daniel MenoldSELL1000023.58
2024-01-16Paul T. QuinlanSELL500023.58
2024-01-10Janet DorlingSELL600023.86
2023-12-18Charles McwherterSELL1133221.48
2023-12-15Daniel MenoldSELL2149721.99
2023-12-15Paul T. QuinlanSELL500021.98
2023-12-11Janet DorlingSELL600020.07
2023-12-11Sujal ShahSELL6486520
2023-11-17Charles McwherterSELL1134218.28
2023-11-15Paul T. QuinlanSELL500017.38
2023-10-18Charles McwherterSELL2174314.07
2023-10-16Paul T. QuinlanSELL500013.76
2023-10-09Sujal ShahSELL6486114.2
2023-09-29Kurt Von EmsterSELL1592115.68
2023-09-18Charles McwherterSELL2174616.22
2023-09-15Paul T. QuinlanSELL5300016.87
2023-08-18Charles McwherterSELL2174611.47
2023-08-15Paul T. QuinlanSELL500011.91

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cymabay Therapeu compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.2960.558-153%-0.211-29%0.053-657%0.060-596%
Book Value Per Share--2.5461.810+41%0.623+309%1.352+88%0.929+174%
Current Ratio--10.96012.866-15%12.023-9%13.721-20%9.723+13%
Debt To Asset Ratio--0.3280.425-23%0.592-45%0.272+21%0.345-5%
Debt To Equity Ratio--0.4870.829-41%1.648-70%0.582-16%0.942-48%
Dividend Per Share----0%-0%-0%-0%
Eps---0.365-0.229-37%-0.231-37%-0.198-46%-0.137-62%
Free Cash Flow Per Share---0.240-0.159-34%-0.183-24%-0.161-33%-0.112-53%
Free Cash Flow To Equity Per Share---0.2160.594-136%-0.077-65%0.110-297%0.093-331%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---7.377--------
Intrinsic Value_10Y_min---10.124--------
Intrinsic Value_1Y_max---0.490--------
Intrinsic Value_1Y_min---0.723--------
Intrinsic Value_3Y_max---1.662--------
Intrinsic Value_3Y_min---2.439--------
Intrinsic Value_5Y_max---3.063--------
Intrinsic Value_5Y_min---4.431--------
Market Cap3728216800.000+27%2711221700.0001670121750.000+62%454261637.500+497%777266627.500+249%744036370.000+264%
Net Profit Margin---735.123-183.787-75%--100%-36.757-95%-18.559-97%
Operating Margin---745.579-186.364-75%--100%-37.273-95%-18.812-97%
Operating Ratio--746.579186.897+299%-+100%37.379+1897%19.021+3825%
Pb Ratio12.757+27%9.2778.931+4%8.503+9%5.645+64%24.312-62%
Pe Ratio-22.244-38%-16.176-106.598+559%-4.298-73%-26.923+66%-26.475+64%
Price Per Share32.480+27%23.62014.550+62%3.958+497%6.772+249%6.482+264%
Price To Free Cash Flow Ratio-33.819-38%-24.594-3.288-87%-5.646-77%-7.528-69%-17.724-28%
Price To Total Gains Ratio-109.863-38%-79.89560.147-233%-18.886-76%-7.899-90%-50.684-37%
Quick Ratio--15.79619.338-18%20.409-23%21.815-28%15.655+1%
Return On Assets---0.096-0.080-18%-0.189+96%-0.123+27%-0.148+53%
Return On Equity---0.143-0.148+3%-0.531+270%-0.216+51%-0.393+174%
Total Gains Per Share---0.2960.558-153%-0.211-29%0.053-657%0.060-596%
Usd Book Value--292256000.000207761000.000+41%71542500.000+309%155228750.000+88%106654000.000+174%
Usd Book Value Change Per Share---0.2960.558-153%-0.211-29%0.053-657%0.060-596%
Usd Book Value Per Share--2.5461.810+41%0.623+309%1.352+88%0.929+174%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.365-0.229-37%-0.231-37%-0.198-46%-0.137-62%
Usd Free Cash Flow---27560000.000-18244000.000-34%-21057000.000-24%-18484350.000-33%-12819600.000-53%
Usd Free Cash Flow Per Share---0.240-0.159-34%-0.183-24%-0.161-33%-0.112-53%
Usd Free Cash Flow To Equity Per Share---0.2160.594-136%-0.077-65%0.110-297%0.093-331%
Usd Market Cap3728216800.000+27%2711221700.0001670121750.000+62%454261637.500+497%777266627.500+249%744036370.000+264%
Usd Price Per Share32.480+27%23.62014.550+62%3.958+497%6.772+249%6.482+264%
Usd Profit---41902000.000-27919000.000-33%-31370750.000-25%-24047550.000-43%-16379325.000-61%
Usd Revenue--57000.0007768250.000-99%-+100%1553650.000-96%1276825.000-96%
Usd Total Gains Per Share---0.2960.558-153%-0.211-29%0.053-657%0.060-596%
 EOD+5 -3MRQTTM+10 -23YOY+13 -205Y+10 -2310Y+14 -19

4.2. Fundamental Score

Let's check the fundamental score of Cymabay Therapeu based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-22.244
Price to Book Ratio (EOD)Between0-112.757
Net Profit Margin (MRQ)Greater than0-735.123
Operating Margin (MRQ)Greater than0-745.579
Quick Ratio (MRQ)Greater than115.796
Current Ratio (MRQ)Greater than110.960
Debt to Asset Ratio (MRQ)Less than10.328
Debt to Equity Ratio (MRQ)Less than10.487
Return on Equity (MRQ)Greater than0.15-0.143
Return on Assets (MRQ)Greater than0.05-0.096
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Cymabay Therapeu based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5080.992
Ma 20Greater thanMa 5032.349
Ma 50Greater thanMa 10028.590
Ma 100Greater thanMa 20024.228
OpenGreater thanClose32.490
Total5/5 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -326256-70-54-12462-62206144
Net Interest Income  -3,156766-2,390399-1,991318-1,6732,272599



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets434,686
Total Liabilities142,430
Total Stockholder Equity292,256
 As reported
Total Liabilities 142,430
Total Stockholder Equity+ 292,256
Total Assets = 434,686

Assets

Total Assets434,686
Total Current Assets403,802
Long-term Assets30,884
Total Current Assets
Cash And Cash Equivalents 206,535
Short-term Investments 187,720
Other Current Assets 9,547
Total Current Assets  (as reported)403,802
Total Current Assets  (calculated)403,802
+/-0
Long-term Assets
Property Plant Equipment 5,725
Long Term Investments 21,932
Long-term Assets Other 2,799
Long-term Assets  (as reported)30,884
Long-term Assets  (calculated)30,456
+/- 428

Liabilities & Shareholders' Equity

Total Current Liabilities36,843
Long-term Liabilities105,587
Total Stockholder Equity292,256
Total Current Liabilities
Short-term Debt 10,007
Short Long Term Debt 10,000
Accounts payable 3,828
Other Current Liabilities 21,319
Total Current Liabilities  (as reported)36,843
Total Current Liabilities  (calculated)45,154
+/- 8,311
Long-term Liabilities
Long term Debt 99,172
Capital Lease Obligations 5,322
Long-term Liabilities  (as reported)105,587
Long-term Liabilities  (calculated)104,494
+/- 1,093
Total Stockholder Equity
Common Stock11
Retained Earnings -978,227
Accumulated Other Comprehensive Income 144
Other Stockholders Equity 1,270,328
Total Stockholder Equity (as reported)292,256
Total Stockholder Equity (calculated)292,256
+/-0
Other
Capital Stock11
Cash and Short Term Investments 394,255
Common Stock Shares Outstanding 113,323
Current Deferred Revenue1,689
Liabilities and Stockholders Equity 434,686
Net Debt -92,041
Net Invested Capital 401,428
Net Working Capital 366,959
Property Plant and Equipment Gross 9,155
Short Long Term Debt Total 114,494



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
8,116
0
0
32,200
32,500
31,196
26,033
44,649
37,474
34,730
28,670
48,863
43,079
36,770
30,475
24,786
19,359
25,379
18,732
104,344
104,247
232,259
218,168
203,708
186,747
274,157
253,435
231,800
205,727
188,600
176,597
168,486
153,825
136,682
117,041
122,902
202,318
200,642
177,724
159,247
141,852
245,319
226,650
451,048
434,686
434,686451,048226,650245,319141,852159,247177,724200,642202,318122,902117,041136,682153,825168,486176,597188,600205,727231,800253,435274,157186,747203,708218,168232,259104,247104,34418,73225,37919,35924,78630,47536,77043,07948,86328,67034,73037,47444,64926,03331,19632,50032,200008,116
   > Total Current Assets 
0
0
0
32,100
32,239
30,933
25,432
44,399
37,229
34,492
28,303
48,573
42,794
36,490
30,164
24,480
18,528
24,557
17,869
103,659
103,544
231,176
216,715
202,255
181,562
270,064
249,813
227,771
202,923
185,949
174,102
166,129
151,585
133,273
113,813
119,576
191,099
192,046
166,611
155,124
138,073
242,720
224,071
447,659
403,802
403,802447,659224,071242,720138,073155,124166,611192,046191,099119,576113,813133,273151,585166,129174,102185,949202,923227,771249,813270,064181,562202,255216,715231,176103,544103,65917,86924,55718,52824,48030,16436,49042,79448,57328,30334,49237,22944,39925,43230,93332,23932,100000
       Cash And Cash Equivalents 
7,726
0
0
32,100
24,401
22,342
8,002
16,356
11,586
10,841
11,702
6,691
7,706
21,197
12,411
6,821
10,495
13,673
9,509
23,009
23,054
65,581
44,726
41,795
48,995
125,574
28,081
43,462
24,869
56,794
96,051
47,273
28,193
43,326
32,897
68,963
125,806
73,995
52,753
30,691
20,291
59,150
35,482
273,721
206,535
206,535273,72135,48259,15020,29130,69152,75373,995125,80668,96332,89743,32628,19347,27396,05156,79424,86943,46228,081125,57448,99541,79544,72665,58123,05423,0099,50913,67310,4956,82112,41121,1977,7066,69111,70210,84111,58616,3568,00222,34224,40132,100007,726
       Short-term Investments 
0
0
0
0
6,843
6,191
15,624
26,270
23,209
21,950
15,329
40,162
33,774
14,057
16,705
16,313
6,499
9,723
7,217
79,160
74,156
163,955
167,353
156,350
129,669
139,182
213,126
175,132
166,076
119,438
72,856
113,991
118,130
82,132
73,237
44,825
60,729
114,564
111,130
122,724
115,194
177,215
178,362
165,057
187,720
187,720165,057178,362177,215115,194122,724111,130114,56460,72944,82573,23782,132118,130113,99172,856119,438166,076175,132213,126139,182129,669156,350167,353163,95574,15679,1607,2179,7236,49916,31316,70514,05733,77440,16215,32921,95023,20926,27015,6246,1916,8430000
       Net Receivables 
0
0
0
0
178
258
144
237
347
199
100
209
186
96
19
22
0
0
0
0
5,000
5,000
405
217
0
481
725
509
687
377
209
284
277
265
227
69
0
0
0
0
2,909
1,733
0
0
0
0001,7332,90900006922726527728420937768750972548102174055,0005,00000002219961862091001993472371442581780000
       Inventory 
0
0
0
0
364
1,876
1,475
1,402
1,991
1,363
996
1,491
0
0
0
0
0
0
0
0
1,208
0
2,131
1,793
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000001,7932,13101,208000000001,4919961,3631,9911,4021,4751,8763640000
   > Long-term Assets 
0
0
0
100
261
263
601
250
245
238
367
290
285
280
311
306
831
822
863
685
703
1,083
1,453
1,453
5,185
4,093
3,622
4,029
2,804
2,651
2,495
2,357
2,240
3,409
3,228
3,326
11,219
8,596
11,113
4,123
3,779
2,599
2,579
3,389
30,884
30,8843,3892,5792,5993,7794,12311,1138,59611,2193,3263,2283,4092,2402,3572,4952,6512,8044,0293,6224,0935,1851,4531,4531,083703685863822831306311280285290367238245250601263261100000
       Property Plant Equipment 
84
0
0
9
3
60
87
91
86
80
75
69
64
59
90
85
77
68
59
51
69
103
90
90
2,905
2,971
2,892
2,768
2,644
2,491
2,335
2,197
2,033
1,963
1,781
1,605
1,432
1,263
1,213
1,042
870
866
725
510
5,725
5,7255107258668701,0421,2131,2631,4321,6051,7811,9632,0332,1972,3352,4912,6442,7682,8922,9712,905909010369515968778590596469758086918760390084
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,067
4,885
6,874
0
0
0
0
0
21,932
21,932000006,8744,8858,067000000000000000000000000000000000000
       Long-term Assets Other 
0
0
0
91
258
203
514
159
159
158
292
221
221
221
221
221
754
754
804
634
634
980
1,363
1,363
2,280
1,122
730
1,261
160
160
160
-113,831
-117,923
1,446
1,447
1,721
1,720
2,448
3,026
3,081
2,909
1,733
1,854
2,879
2,799
2,7992,8791,8541,7332,9093,0813,0262,4481,7201,7211,4471,446-117,923-113,8311601601601,2617301,1222,2801,3631,36398063463480475475422122122122122129215815915951420325891000
> Total Liabilities 
17,986
0
0
12,100
13,904
19,820
17,556
18,518
23,624
16,462
10,990
15,369
14,964
14,924
15,054
14,574
15,422
16,152
16,593
17,840
19,300
20,060
18,955
15,577
16,329
16,526
17,376
19,209
19,379
13,552
10,989
11,851
11,119
9,036
9,947
35,844
69,381
93,261
95,267
99,069
105,698
141,130
118,242
124,857
142,430
142,430124,857118,242141,130105,69899,06995,26793,26169,38135,8449,9479,03611,11911,85110,98913,55219,37919,20917,37616,52616,32915,57718,95520,06019,30017,84016,59316,15215,42214,57415,05414,92414,96415,36910,99016,46223,62418,51817,55619,82013,90412,1000017,986
   > Total Current Liabilities 
17,854
0
0
2,200
9,488
15,521
13,757
15,032
20,459
13,664
8,545
6,153
6,146
6,747
7,542
7,751
9,311
10,780
11,988
14,028
16,310
17,918
16,916
13,640
14,415
14,473
15,422
17,358
17,636
11,922
9,478
10,462
9,857
7,909
8,959
11,741
18,366
14,039
12,560
12,711
15,441
46,500
17,894
19,666
36,843
36,84319,66617,89446,50015,44112,71112,56014,03918,36611,7418,9597,9099,85710,4629,47811,92217,63617,35815,42214,47314,41513,64016,91617,91816,31014,02811,98810,7809,3117,7517,5426,7476,1466,1538,54513,66420,45915,03213,75715,5219,4882,2000017,854
       Short-term Debt 
0
0
0
0
38
410
795
1,193
1,355
1,403
1,450
0
509
1,262
2,041
2,607
2,700
2,797
2,897
3,001
3,108
3,219
0
0
0
357
373
389
407
424
443
462
482
502
523
545
567
590
614
639
664
537
374
206
10,007
10,0072063745376646396145905675455235024824624434244073893733570003,2193,1083,0012,8972,7972,7002,6072,0411,26250901,4501,4031,3551,193795410380000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
1,355
0
0
0
509
0
0
0
2,700
2,797
7,496
3,001
3,108
3,219
0
0
0
357
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,000
10,0000000000000000000003570003,2193,1083,0017,4962,7972,7000005090001,35500000000
       Accounts payable 
657
0
0
1,000
697
1,069
1,262
1,047
2,085
1,527
1,721
707
1,008
1,777
1,272
935
899
1,096
1,101
1,235
1,311
2,038
1,336
1,629
1,973
2,410
2,882
1,494
2,503
1,213
476
947
231
1,606
1,050
764
2,728
199
866
479
1,096
1,633
4,589
2,731
3,828
3,8282,7314,5891,6331,0964798661992,7287641,0501,6062319474761,2132,5031,4942,8822,4101,9731,6291,3362,0381,3111,2351,1011,0968999351,2721,7771,0087071,7211,5272,0851,0471,2621,0696971,00000657
       Other Current Liabilities 
3,460
0
0
1,200
6,919
11,638
8,888
8,766
13,596
7,704
2,181
5,446
1,220
900
1,259
1,177
1,145
6,680
7,783
9,585
6,091
7,648
15,580
12,011
12,442
11,706
12,167
15,475
14,726
10,285
8,559
9,053
9,144
5,801
7,386
10,432
15,638
13,250
11,080
11,593
13,681
10,597
11,299
15,097
21,319
21,31915,09711,29910,59713,68111,59311,08013,25015,63810,4327,3865,8019,1449,0538,55910,28514,72615,47512,16711,70612,44212,01115,5807,6486,0919,5857,7836,6801,1451,1771,2599001,2205,4462,1817,70413,5968,7668,88811,6386,9191,200003,460
   > Long-term Liabilities 
0
0
0
9,900
4,416
4,299
3,799
3,486
3,165
2,798
2,445
9,216
8,818
8,177
7,512
6,823
6,111
5,372
4,605
3,812
2,990
2,142
2,039
1,937
1,914
2,053
1,954
1,851
1,743
1,630
1,511
1,389
1,262
1,127
988
24,103
51,015
79,222
82,707
86,358
90,257
94,630
100,348
105,191
105,587
105,587105,191100,34894,63090,25786,35882,70779,22251,01524,1039881,1271,2621,3891,5111,6301,7431,8511,9542,0531,9141,9372,0392,1422,9903,8124,6055,3726,1116,8237,5128,1778,8189,2162,4452,7983,1653,4863,7994,2994,4169,900000
       Long term Debt Total 
0
0
0
4,374
4,407
4,099
3,793
3,476
3,152
2,784
2,429
9,198
8,799
8,159
7,496
6,809
6,098
5,362
4,599
3,809
2,990
2,142
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000002,1422,9903,8094,5995,3626,0986,8097,4968,1598,7999,1982,4292,7843,1523,4763,7934,0994,4074,374000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-38
-410
-795
-1,193
-1,355
-1,403
-1,450
0
-509
-1,262
-2,041
-2,607
-2,700
-2,797
-2,897
-3,001
-3,108
-3,219
0
0
0
2,053
1,954
1,851
1,743
1,630
1,511
1,389
1,262
1,127
988
844
695
537
374
206
30
0
0
0
-4,685
-4,685000302063745376958449881,1271,2621,3891,5111,6301,7431,8511,9542,053000-3,219-3,108-3,001-2,897-2,797-2,700-2,607-2,041-1,262-5090-1,450-1,403-1,355-1,193-795-410-380000
       Long-term Liabilities Other 
0
0
0
0
9
200
6
10
13
14
16
18
19
18
16
14
13
10
6
3
0
0
0
0
0
2,053
1,954
1,851
0
0
0
0
0
0
0
24,103
51,015
79,222
82,707
86,358
90,257
0
0
0
0
000090,25786,35882,70779,22251,01524,10300000001,8511,9542,05300000361013141618191816141310620090000
       Deferred Long Term Liability 
0
0
0
5,441
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,039
1,937
1,914
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,9141,9372,0390000000000000000005,441000
> Total Stockholder Equity
0
0
0
20,100
18,596
11,376
8,477
26,131
13,850
18,268
17,680
33,494
28,115
21,846
15,421
10,212
3,937
9,227
2,139
86,504
84,947
212,199
199,213
188,131
170,418
257,631
236,059
212,591
186,348
175,048
165,608
156,635
142,706
127,646
107,094
87,058
132,937
107,381
82,457
60,178
36,154
104,189
108,408
326,191
292,256
292,256326,191108,408104,18936,15460,17882,457107,381132,93787,058107,094127,646142,706156,635165,608175,048186,348212,591236,059257,631170,418188,131199,213212,19984,94786,5042,1399,2273,93710,21215,42121,84628,11533,49417,68018,26813,85026,1318,47711,37618,59620,100000
   Common Stock
0
0
0
1
1
1
1
1
1
1
1
2
2
2
2
2
2
3
3
4
4
6
6
6
6
7
7
7
7
7
7
7
7
7
7
7
8
8
8
8
8
17
17
18
11
1118171788888777777777776666443322222211111111000
   Retained Earnings Total Equity000-901,635-872,857-846,224-821,719-794,625-766,856-740,313-717,631-694,409-676,858-661,107-649,686-638,9600-596,459-570,177-546,139-523,064-503,615-485,052-467,521-450,516-445,473-437,239-428,310-422,959-416,007-410,128-403,136-396,288-390,309-384,444-383,087-380,759-368,037-362,076-358,904-348,842-344,928000
   Accumulated Other Comprehensive Income 
0
0
0
-3,300
2
3
-225
-15
-14
-7
-13
-8
-21
-1
-5
-2
-1
-2
-1
-13
-44
-132
-67
-31
-58
45
228
177
80
-130
186
82
8
-6
1
-1
-13
-219
-441
-574
-326
-70
-124
-62
144
144-62-124-70-326-574-441-219-13-11-6882186-1308017722845-58-31-67-132-44-13-1-2-1-2-5-1-21-8-13-7-14-15-22532-3,300000
   Capital Surplus 
0
0
0
365,033
367,435
370,276
370,552
394,182
394,622
401,361
402,136
423,809
424,422
424,981
425,552
426,219
426,895
437,536
439,376
531,986
535,503
679,846
684,326
691,771
693,534
803,718
806,001
808,866
812,133
814,131
815,101
817,653
819,549
822,054
824,717
827,365
899,798
902,217
904,609
906,968
909,329
1,005,877
0
0
0
0001,005,877909,329906,968904,609902,217899,798827,365824,717822,054819,549817,653815,101814,131812,133808,866806,001803,718693,534691,771684,326679,846535,503531,986439,376437,536426,895426,219425,552424,981424,422423,809402,136401,361394,622394,182370,552370,276367,435365,033000
   Treasury Stock0000000000000000000000000000000000000-26,131-8,477-11,376-18,5960000
   Other Stockholders Equity 
0
0
0
336,135
367,435
370,276
370,552
394,182
394,622
401,361
402,136
423,809
424,422
424,981
425,552
426,219
426,895
437,536
439,376
531,986
535,503
679,846
684,326
691,771
693,534
803,718
806,001
808,866
812,133
814,131
815,101
817,653
819,549
822,054
824,717
827,365
899,798
902,217
904,609
906,968
909,329
1,005,877
1,010,958
1,262,560
1,270,328
1,270,3281,262,5601,010,9581,005,877909,329906,968904,609902,217899,798827,365824,717822,054819,549817,653815,101814,131812,133808,866806,001803,718693,534691,771684,326679,846535,503531,986439,376437,536426,895426,219425,552424,981424,422423,809402,136401,361394,622394,182370,552370,276367,435336,135000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue31,073
Cost of Revenue-681
Gross Profit30,39230,392
 
Operating Income (+$)
Gross Profit30,392
Operating Expense-132,071
Operating Income-101,679-101,679
 
Operating Expense (+$)
Research Development80,118
Selling General Administrative51,953
Selling And Marketing Expenses0
Operating Expense132,071132,071
 
Net Interest Income (+$)
Interest Income8,731
Interest Expense-18,945
Other Finance Cost-1,006
Net Interest Income-9,208
 
Pretax Income (+$)
Operating Income-101,679
Net Interest Income-9,208
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-105,370-97,988
EBIT - interestExpense = -120,624
-105,370
-86,425
Interest Expense18,945
Earnings Before Interest and Taxes (EBIT)-101,679-86,425
Earnings Before Interest and Taxes (EBITDA)-100,998
 
After tax Income (+$)
Income Before Tax-105,370
Tax Provision-0
Net Income From Continuing Ops-90,101-105,370
Net Income-105,370
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses132,752
Total Other Income/Expenses Net-3,6919,208
 

Technical Analysis of Cymabay
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cymabay. The general trend of Cymabay is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cymabay's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cymabay Therapeu.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: .

The bearish price targets are: 32.35 > 32.16 > 25.37.

Tweet this
Cymabay Therapeu Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cymabay Therapeu. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cymabay Therapeu Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cymabay Therapeu. The current macd is 0.98443216.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cymabay price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Cymabay. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Cymabay price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Cymabay Therapeu Daily Moving Average Convergence/Divergence (MACD) ChartCymabay Therapeu Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cymabay Therapeu. The current adx is 69.22.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cymabay shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Cymabay Therapeu Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cymabay Therapeu. The current sar is 32.16.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Cymabay Therapeu Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cymabay Therapeu. The current rsi is 80.99. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Cymabay Therapeu Daily Relative Strength Index (RSI) ChartCymabay Therapeu Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cymabay Therapeu. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cymabay price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Cymabay Therapeu Daily Stochastic Oscillator ChartCymabay Therapeu Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cymabay Therapeu. The current cci is 92.57.

Cymabay Therapeu Daily Commodity Channel Index (CCI) ChartCymabay Therapeu Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cymabay Therapeu. The current cmo is 66.63.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Cymabay Therapeu Daily Chande Momentum Oscillator (CMO) ChartCymabay Therapeu Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cymabay Therapeu. The current willr is -5.88235294.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Cymabay Therapeu Daily Williams %R ChartCymabay Therapeu Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cymabay Therapeu.

Cymabay Therapeu Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cymabay Therapeu. The current atr is 0.25580074.

Cymabay Therapeu Daily Average True Range (ATR) ChartCymabay Therapeu Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cymabay Therapeu. The current obv is 213,836,311.

Cymabay Therapeu Daily On-Balance Volume (OBV) ChartCymabay Therapeu Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cymabay Therapeu. The current mfi is 94.21.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Cymabay Therapeu Daily Money Flow Index (MFI) ChartCymabay Therapeu Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cymabay Therapeu.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-10-30BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-02STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-16STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-04MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside

6.3. Candlestick Patterns

Cymabay Therapeu Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cymabay Therapeu based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5080.992
Ma 20Greater thanMa 5032.349
Ma 50Greater thanMa 10028.590
Ma 100Greater thanMa 20024.228
OpenGreater thanClose32.490
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cymabay with someone you think should read this too:
  • Are you bullish or bearish on Cymabay? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cymabay? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cymabay Therapeu

I send you an email if I find something interesting about Cymabay Therapeu.


Comments

How you think about this?

Leave a comment

Stay informed about Cymabay Therapeu.

Receive notifications about Cymabay Therapeu in your mailbox!